Andrew D.C. LaFrence - Mar 15, 2022 Form 4 Insider Report for Vyant Bio, Inc. (VYNT)

Role: Chief Financial Officer
Signature: /s/ Andrew LaFrence
Stock symbol: VYNT
Transactions as of: Mar 15, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/17/2022, 04:15 PM
Previous filing: Dec 29, 2021
Next filing: Jul 18, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VYNT	Stock option (right to buy)	Award	$0	+110K		$0.00	110K	Mar 15, 2022	Common Stock	110K	$1.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date.

Content

The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date.